INTRODUCTION AND OBJECTIVES: Sparse data exists regarding the impact of histological variants on survival outcomes in candidates to radical cystectomy (RC). We benefit from the largest multicenter collaboration available in the literature to evaluate incidence and impact on survival of histological variants at RC.
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METHODS: We focused on 2,332 patients treated with RC and pelvic lymph node dissection, between 1990 and 2018, at several American and European tertiary referral centers. All specimens were evaluated by dedicated uropatholgists. Univariable and multivariable competing risk regression analyses tested the effect off different histopathological findings on recurrence, cancer specific mortality (CSM) and overall mortality (OM).
RESULTS: Overall, 296 (13%) and 527 (23%) patients were found with histological variants at TUR and RC, respectively. At TUR, considering histological variants, 19 (0.8%) were sarcomatoid, 2 (0.1%) lymphoepitelial, 17 (0.7%) small cell, 107 (4.6%) squamous, 22 (0.9%) micropapillary, 20 (0.9%) neuroendocrine, 7 (0.3%) glandular, 29 (1.2%) adenocarcinoma, 21 (0.9%) mixed and 52 (2.2%) other type of histological variants. At RC, considering histological variants, 63 (2.7%) were sarcomatoid, 1 (0.1%) lymphoepitelial, 19 (0.8%) small cell, 152 (6.5%) squamous, 77 (3.3%) micropapillary, 14 (0.6%) neuroendocrine, 21 (0.9%) glandular, 34 (1.5%) adenocarcinoma, 57 (2.4%) mixed and 89 (3.8%) other type of histological variants. The higher concordance between TUR and RC was find in sarcomatoid (63%) and small cell carcinoma (82%) patients. With a median follow-up of 6.8 years, 831 recurrence, 666 CSM, and 1,039 OM were recorded, respectively. At multivariable Cox regression analyses, the presence of sarcomatoid variant was associated with higher CSM ( 
INTRODUCTION AND OBJECTIVES:
The 5-year bladder cancer recurrence rate after radical cystectomy (RC) ranges 15%-70%; 30% of these patients are diagnosed with local recurrence (LR). Cisplatin-based chemotherapy (CHT) is the standard treatment for LR, whilst radiotherapy (RT) and surgery have marginal roles. However, salvage treatments are rarely curative. The aims of the present study are: to describe patterns of LR; to identify the most effective salvage treatments and any predictors of CSS and OS.
